Company intelligence / Profile preview
Chengdu Genevector Biotechnology Co. Ltd.
Chengdu, Sichuan Sheng, Chinajwksw.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Genevector is a leading Chinese biotech company specializing in the development and manufacturing of adeno-associated virus (AAV)-based gene therapies targeting ophthalmic, neuromuscular, and metabolic genetic disorders. The company has advanced several candidates into early clinical stages with a robust proprietary platform supporting both R&D and GMP-compliant production. Notable programs include JWK‑001 for wet AMD in Phase I/II trials and JWK‑008 for MPS I currently in Phase I. No published clinical results yet.
- Therapeutic areas
- Rare DiseasesOphthalmology
- Modalities
- AAV-based gene therapyLentiviral vectors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Chengdu Genevector Biotechnology Co. Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Genevector Biotechnology Co. Ltd..